AI-Based Risk Prediction Model for Upper Digestive Tract Cancer
Development of Artificial Intelligence Risk Prediction Model for Upper Digestive Tract Cancer Using High Resolution Endoscopic Image, Digital Pathology, Genetics, and Oro-gastro-intestinal Microbiota.
Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development. This prospective multicenter cohort study aims to establish a longitudinal database integrating clinical information, endoscopic findings, pathology, genetics, epigenetics, and gastrointestinal microbiota data from subjects undergoing upper digestive tract endoscopy.
The study will develop explainable artificial intelligence (AI)-based risk prediction models to identify factors associated with disease progression, treatment response, and cancer development. Participants will be followed longitudinally to evaluate changes in lesion severity and clinical outcomes.
研究概览
详细说明
Objectives:
There is no solid evidence about the risk prediction model and screening duration for upper digestive tract pre-malignant lesions and its progression. There is also no longitudinal study combining multi-omic approach, endoscopic and pathologic images and the association with disease development. Hence we design a prospective cohort targeting upper digestive tract disease progression and cancer development, with standardized clinical data collection, quality control and explainable AI (artificial intellegence) model for better reliability of risk prediction model.
Aims:
We aim to develop risk prediction model for the progression of upper digestive tract disease and cancer development.
Methods:
The study is disigned as a multi-center prospective cohort, targeting subjects undergoing upper digestive tract endoscopy. The development of AI risk prediction models will combine endoscopic pre-malignant lesion, pathology, genetics, epigenetics, oro-gastro-intestinal microbiota, and follow-up longitudinally with change in lesion severity, medication response, cancer development.
Outcome measurement:
Primary endpoints: upper digestive tract cancer development. Secondary endpoints: progression in pre-malignant lesions, recurrent colon polyps, other cancer developement, metabolic and cardiovascular disease, response to medication in gastro-esophageal reflux and dyspepsia population.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Jyh-Ming Liou, MD, PhD
- 电话号码：+886972651883
- 邮箱：jyhmingliou@gmail.com
研究联系人备份
- 姓名：Tzu-Chan Hong, MD, PhD
- 电话号码：238061 +886-2-2322-0322
- 邮箱：edisonhong77@gmail.com
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
- Patients with a history of surgery involving the esophagus, stomach, or duodenum.
- Patients with gastric deformity secondary to severe gastric inflammation.
- Patients unable to undergo regular follow-up upper gastrointestinal endoscopy every 1-3 years.
- Patients with severe comorbidities that preclude follow-up upper gastrointestinal endoscopy or with an estimated life expectancy of less than 10 years.
描述
Inclusion Criteria:
- Patients undergoing upper gastrointestinal endoscopy.
Patients with at least one of the following conditions or indications:
- Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test);
- Dyspeptic symptoms;
- Gastroesophageal reflux disease;
- History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma;
- Barrett's esophagus;
- Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis);
- Gastric subepithelial lesions.
Exclusion Criteria:
-
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with upper digestive tract cancer confirmed by histopathological examination
大体时间："From enrollment to the end of follow-up at 10 years"
|
Upper digestive tract cancer development will be defined as newly diagnosed upper digestive tract malignancy during follow-up, including esophageal cancer and gastric cancer.
Diagnosis will be confirmed by histopathological examination of biopsy or resection specimens.
|
"From enrollment to the end of follow-up at 10 years"
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recurrent colon polyps
大体时间：From enrollment to the end of follow-up at 10 years
|
From enrollment to the end of follow-up at 10 years
|
|
|
Number of participants with progression of gastric premalignant lesions assessed by OLGA, OLGIM, and EGGIM staging systems
大体时间：From enrollment to the end of follow-up at 10 years
|
Progression of premalignant lesions will be defined as worsening of gastric atrophy and intestinal metaplasia during follow-up based on histological and endoscopic assessment.
Histological progression will be evaluated using changes in OLGA and OLGIM stages, while endoscopic progression will be assessed using EGGIM scores.
Progression is defined as an increase in stage or score compared with baseline evaluation.
|
From enrollment to the end of follow-up at 10 years
|
|
Number of participants with non-upper digestive tract malignancies confirmed by histopathological examination
大体时间：From enrollment to the end of follow-up at 10 years
|
Other cancer development will be defined as newly diagnosed malignancies other than upper digestive tract cancers during follow-up, including but not limited to colorectal cancer, hepatobiliary cancer, pancreatic cancer, lung cancer, breast cancer, prostate cancer, and hematologic malignancies.
Diagnosis will be confirmed by histopathological examination, imaging findings, or cancer registry records.
|
From enrollment to the end of follow-up at 10 years
|
|
Number of participants with newly diagnosed metabolic and cardiovascular diseases
大体时间：From enrollment to the end of follow-up at 10 years
|
Metabolic and cardiovascular disease development will be defined as newly diagnosed metabolic or cardiovascular conditions during follow-up, including diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, cerebrovascular disease, heart failure, and peripheral arterial disease.
Diagnoses will be confirmed based on medical records and clinical assessments.
|
From enrollment to the end of follow-up at 10 years
|
|
Number of participants with symptom or endoscopic improvement after medication treatment in gastroesophageal reflux disease and dyspepsia populations
大体时间：From enrollment to the end of follow-up at 10 years
|
Treatment response will be defined as improvement of reflux and dyspeptic symptoms after medical therapy during follow-up.
Symptom response will be assessed based on patient-reported symptom improvement and medical records.
Endoscopic response will be assessed endoscopically
|
From enrollment to the end of follow-up at 10 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.